APO Research
Talk to an analyst

APO RESEARCH · REPORT

GLP-1 Targeted Peptide Weight Loss Drugs

Compare research editions
View pricing & licenses

Selected research

Market Outlook & Growth Opportunities

Global GLP-1 Targeted Peptide Weight Loss Drugs Market Outlook and Growth Opportunities 2026

27 December 2025219 pages

Choose your research edition.

Industry ResearchGLP-1 Targeted Peptide Weight Loss Drugs Industry Research Report 2026146 pages · $2,950 USDIndustry Growth & TrendsGlobal GLP-1 Targeted Peptide Weight Loss Drugs Industry Growth and Trends Forecast to 2032122 pages · $3,450 USDMarket StructureGlobal GLP-1 Targeted Peptide Weight Loss Drugs Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal GLP-1 Targeted Peptide Weight Loss Drugs Market Outlook and Growth Opportunities 2026219 pages · $4,250 USDMarket Analysis & ForecastGlobal GLP-1 Targeted Peptide Weight Loss Drugs Market Analysis and Forecast 2026-2032212 pages · $4,950 USD

Market perspective

The global GLP-1 Targeted Peptide Weight Loss Drugs market was valued at US$ million in 2026 and is projected to reach US$ million by 2032, implying a compound annual growth rate (CAGR) of % over 2026-2032.

The North America market for GLP-1 Targeted Peptide Weight Loss Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

The Europe market for GLP-1 Targeted Peptide Weight Loss Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Read the full market overview

The Asia Pacific market for GLP-1 Targeted Peptide Weight Loss Drugs is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

In China, the GLP-1 Targeted Peptide Weight Loss Drugs market is projected to increase from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026-2032.

Major global companies in the GLP-1 Targeted Peptide Weight Loss Drugs market include Chugai Pharmaceutical, Benemae Pharmaceutical, Qilu Pharmaceutical, Jiuyuan Gene Engineering, Huadong Medicine, Zealand Pharma, The General Hospital Corp, Sanofi-Aventis and QuiaPEG Pharmaceuticals Ab, among others. In 2025, the top three vendors together accounted for approximately % of global revenue.

This report provides an overview of the global GLP-1 Targeted Peptide Weight Loss Drugs market in terms of sales, revenue, and price, analyzing global market trends using historical revenue and sales data for 2021-2025, estimates for 2026, and projected CAGRs through 2032.

The study covers key producers of GLP-1 Targeted Peptide Weight Loss Drugs and sales in major regions and countries, assesses future market potential, and highlights priority regions and countries for segmenting the market into sub-sectors, with country-specific market value data for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, the Middle East, Africa, and other countries.

The report also presents GLP-1 Targeted Peptide Weight Loss Drugs sales, revenue, market share, and industry ranking for the main manufacturers for 2021-2026, identifies the major stakeholders in the global market, and analyzes their competitive landscape and market positioning based on recent developments and segmental revenues.

In addition, the report analyzes segment data by Type and Application—covering sales, revenue, and price—for 2021-2032, and evaluates and forecasts the GLP-1 Targeted Peptide Weight Loss Drugs market size, projected growth trends, production technologies, key applications, and end-use industries.

GLP-1 Targeted Peptide Weight Loss Drugs Segment by Company

Chugai Pharmaceutical

Benemae Pharmaceutical

Qilu Pharmaceutical

Jiuyuan Gene Engineering

Huadong Medicine

Zealand Pharma

The General Hospital Corp

Sanofi-Aventis

QuiaPEG Pharmaceuticals Ab

Orbis Biosciences

Novo Nordisk

Nano Precision Medical

Nanexa AB

Lexaria Bioscience

iX Biopharma

Intarcia Therapeutics

HIKMA PHARMS

Eli Lilly

Baxter Pharmaceutical

Astra Zeneca

Amylin Pharmaceuticals

GLP-1 Targeted Peptide Weight Loss Drugs Segment by Type

Oral

Injection

GLP-1 Targeted Peptide Weight Loss Drugs Segment by Application

Hospital

Clinic

Others

GLP-1 Targeted Peptide Weight Loss Drugs Segment by Region

North America

United States

Canada

Mexico

Europe

Germany

France

U.K.

Italy

Russia

Spain

Netherlands

Switzerland

Sweden

Poland

Asia-Pacific

China

Japan

South Korea

India

Australia

Taiwan

Southeast Asia

South America

Brazil

Argentina

Chile

Middle East & Africa

Egypt

South Africa

Israel

Türkiye

GCC Countries

Study Objectives

1. To analyze and research the global GLP-1 Targeted Peptide Weight Loss Drugs status and future forecast, involving, sales, revenue, growth rate (CAGR), market share, historical and forecast.

2. To present the key manufacturers, sales, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions GLP-1 Targeted Peptide Weight Loss Drugs market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify GLP-1 Targeted Peptide Weight Loss Drugs significant trends, drivers, influence factors in global and regions.

6. To analyze GLP-1 Targeted Peptide Weight Loss Drugs competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global GLP-1 Targeted Peptide Weight Loss Drugs market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of GLP-1 Targeted Peptide Weight Loss Drugs and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in sales and value), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of GLP-1 Targeted Peptide Weight Loss Drugs.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Provides an overview of the GLP-1 Targeted Peptide Weight Loss Drugs market, including product definition, global market growth prospects, sales value, sales volume, and average price forecasts (2021-2032).

Chapter 2: Analysis key trends, drivers, challenges, and opportunities within the global GLP-1 Targeted Peptide Weight Loss Drugs industry.

Chapter 3: Detailed analysis of GLP-1 Targeted Peptide Weight Loss Drugs manufacturers competitive landscape, price, sales and revenue market share, latest development plan, merger, and acquisition information, etc.

Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 6: Sales and value of GLP-1 Targeted Peptide Weight Loss Drugs in regional level. It provides a quantitative analysis of the market size and development potential of each region and introduces the market development, future development prospects, market space, and market size of each country in the world.

Chapter 7: Sales and value of GLP-1 Targeted Peptide Weight Loss Drugs in country level. It provides sigmate data by type, and by application for each country/region.

Chapter 8: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including product sales, revenue, price, gross margin, product introduction, recent development, etc.

Chapter 9: Analysis of industrial chain, including the upstream and downstream of the industry.

Chapter 10: Concluding Insights.

More report detail

Tables and figures
List of Tables Table 1. GLP-1 Targeted Peptide Weight Loss Drugs Industry Trends Table 2. GLP-1 Targeted Peptide Weight Loss Drugs Industry Drivers Table 3. GLP-1 Targeted Peptide Weight Loss Drugs Industry Opportunities and Challenges Table 4. GLP-1 Targeted Peptide Weight Loss Drugs Industry Restraints Table 5. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Company (US$ Million) & (2021-2026) Table 6. Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue Share by Company (2021-2026) Table 7. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume by Company (K Units) & (2021-2026) Table 8. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume Share by Company (2021-2026) Table 9. Global GLP-1 Targeted Peptide Weight Loss Drugs Average Price (US$/Unit) of Company (2021-2026) Table 10. Global GLP-1 Targeted Peptide Weight Loss Drugs Company Ranking, (2024-2026) & (USD Million) Table 11. Global GLP-1 Targeted Peptide Weight Loss Drugs Key Company Manufacturing Base & Headquarters Table 12. Global GLP-1 Targeted Peptide Weight Loss Drugs Company, Product Type & Application Table 13. Global GLP-1 Targeted Peptide Weight Loss Drugs Company Establishment Date Table 14. Global Company Market Concentration Ratio (CR5 and HHI) Table 15. Global GLP-1 Targeted Peptide Weight Loss Drugs by Company Type (Tier 1, Tier 2, and Tier 3) & (Based on Revenue of 2025) Table 16. Mergers & Acquisitions, Expansion Table 17. Significant Companies of Oral Table 18. Significant Companies of Injection Table 19. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume by Type 2021 VS 2025 VS 2032 (K Units) Table 20. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume by Type (2021-2026) & (K Units) Table 21. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume by Type (2027-2032) & (K Units) Table 22. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume Share by Type (2021-2026) Table 23. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume Share by Type (2027-2032) Table 24. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Type 2021 VS 2025 VS 2032 (US$ Million) Table 25. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Type (2021-2026) & (US$ Million) Table 26. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Type (2027-2032) & (US$ Million) Table 27. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type (2021-2026) Table 28. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type (2027-2032) Table 29. Significant Companies of Hospital Table 30. Significant Companies of Clinic Table 31. Significant Companies of Others Table 32. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume by Application 2021 VS 2025 VS 2032 (K Units) Table 33. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume by Application (2021-2026) & (K Units) Table 34. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume by Application (2027-2032) & (K Units) Table 35. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume Share by Application (2021-2026) Table 36. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume Share by Application (2027-2032) Table 37. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Application 2021 VS 2025 VS 2032 (US$ Million) Table 38. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Application (2021-2026) & (US$ Million) Table 39. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Application (2027-2032) & (US$ Million) Table 40. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application (2021-2026) Table 41. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application (2027-2032) Table 42. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Table 43. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Region (2021-2026) & (K Units) Table 44. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Region (2021-2026) Table 45. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Region (2027-2032) & (K Units) Table 46. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Region (2027-2032) Table 47. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Table 48. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Region (2021-2026) & (US$ Million) Table 49. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Region (2021-2026) Table 50. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Region (2027-2032) & (US$ Million) Table 51. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Region (2027-2032) Table 52. Global GLP-1 Targeted Peptide Weight Loss Drugs Market Average Price (US$/Unit) by Region (2021-2026) Table 53. Global GLP-1 Targeted Peptide Weight Loss Drugs Market Average Price (US$/Unit) by Region (2027-2032) Table 54. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country: 2021 VS 2025 VS 2032 (K Units) Table 55. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Country: 2021 VS 2025 VS 2032 (US$ Million) Table 56. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2021-2026) & (K Units) Table 57. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Country (2021-2026) Table 58. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2027-2032) & (K Units) Table 59. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Country (2027-2032) Table 60. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Country (2021-2026) & (US$ Million) Table 61. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Market Share by Country (2021-2026) Table 62. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Country (2027-2032) & (US$ Million) Table 63. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Market Share by Country (2027-2032) Table 64. Chugai Pharmaceutical Company Information Table 65. Chugai Pharmaceutical Business Overview Table 66. Chugai Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 67. Chugai Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 68. Chugai Pharmaceutical Recent Development Table 69. Benemae Pharmaceutical Company Information Table 70. Benemae Pharmaceutical Business Overview Table 71. Benemae Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 72. Benemae Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 73. Benemae Pharmaceutical Recent Development Table 74. Qilu Pharmaceutical Company Information Table 75. Qilu Pharmaceutical Business Overview Table 76. Qilu Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 77. Qilu Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 78. Qilu Pharmaceutical Recent Development Table 79. Jiuyuan Gene Engineering Company Information Table 80. Jiuyuan Gene Engineering Business Overview Table 81. Jiuyuan Gene Engineering GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 82. Jiuyuan Gene Engineering GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 83. Jiuyuan Gene Engineering Recent Development Table 84. Huadong Medicine Company Information Table 85. Huadong Medicine Business Overview Table 86. Huadong Medicine GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 87. Huadong Medicine GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 88. Huadong Medicine Recent Development Table 89. Zealand Pharma Company Information Table 90. Zealand Pharma Business Overview Table 91. Zealand Pharma GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 92. Zealand Pharma GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 93. Zealand Pharma Recent Development Table 94. The General Hospital Corp Company Information Table 95. The General Hospital Corp Business Overview Table 96. The General Hospital Corp GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 97. The General Hospital Corp GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 98. The General Hospital Corp Recent Development Table 99. Sanofi-Aventis Company Information Table 100. Sanofi-Aventis Business Overview Table 101. Sanofi-Aventis GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 102. Sanofi-Aventis GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 103. Sanofi-Aventis Recent Development Table 104. QuiaPEG Pharmaceuticals Ab Company Information Table 105. QuiaPEG Pharmaceuticals Ab Business Overview Table 106. QuiaPEG Pharmaceuticals Ab GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 107. QuiaPEG Pharmaceuticals Ab GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 108. QuiaPEG Pharmaceuticals Ab Recent Development Table 109. Orbis Biosciences Company Information Table 110. Orbis Biosciences Business Overview Table 111. Orbis Biosciences GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 112. Orbis Biosciences GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 113. Orbis Biosciences Recent Development Table 114. Novo Nordisk Company Information Table 115. Novo Nordisk Business Overview Table 116. Novo Nordisk GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 117. Novo Nordisk GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 118. Novo Nordisk Recent Development Table 119. Nano Precision Medical Company Information Table 120. Nano Precision Medical Business Overview Table 121. Nano Precision Medical GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 122. Nano Precision Medical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 123. Nano Precision Medical Recent Development Table 124. Nanexa AB Company Information Table 125. Nanexa AB Business Overview Table 126. Nanexa AB GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 127. Nanexa AB GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 128. Nanexa AB Recent Development Table 129. Lexaria Bioscience Company Information Table 130. Lexaria Bioscience Business Overview Table 131. Lexaria Bioscience GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 132. Lexaria Bioscience GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 133. Lexaria Bioscience Recent Development Table 134. iX Biopharma Company Information Table 135. iX Biopharma Business Overview Table 136. iX Biopharma GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 137. iX Biopharma GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 138. iX Biopharma Recent Development Table 139. Intarcia Therapeutics Company Information Table 140. Intarcia Therapeutics Business Overview Table 141. Intarcia Therapeutics GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 142. Intarcia Therapeutics GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 143. Intarcia Therapeutics Recent Development Table 144. HIKMA PHARMS Company Information Table 145. HIKMA PHARMS Business Overview Table 146. HIKMA PHARMS GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 147. HIKMA PHARMS GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 148. HIKMA PHARMS Recent Development Table 149. Eli Lilly Company Information Table 150. Eli Lilly Business Overview Table 151. Eli Lilly GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 152. Eli Lilly GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 153. Eli Lilly Recent Development Table 154. Baxter Pharmaceutical Company Information Table 155. Baxter Pharmaceutical Business Overview Table 156. Baxter Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 157. Baxter Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 158. Baxter Pharmaceutical Recent Development Table 159. Astra Zeneca Company Information Table 160. Astra Zeneca Business Overview Table 161. Astra Zeneca GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 162. Astra Zeneca GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 163. Astra Zeneca Recent Development Table 164. Amylin Pharmaceuticals Company Information Table 165. Amylin Pharmaceuticals Business Overview Table 166. Amylin Pharmaceuticals GLP-1 Targeted Peptide Weight Loss Drugs Sales (K Units), Value (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 167. Amylin Pharmaceuticals GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio Table 168. Amylin Pharmaceuticals Recent Development Table 169. Key Raw Materials Table 170. Raw Materials Key Suppliers Table 171. GLP-1 Targeted Peptide Weight Loss Drugs Distributors List Table 172. GLP-1 Targeted Peptide Weight Loss Drugs Customers List Table 173. Research Programs/Design for This Report Table 174. Authors List of This Report Table 175. Secondary Sources Table 176. Primary Sources List of Figures Figure 1. GLP-1 Targeted Peptide Weight Loss Drugs Product Image Figure 2. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value (2021-2032) & (US$ Million) Figure 4. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales (2021-2032) & (K Units) Figure 5. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Average Price (US$/Unit) & (2021-2032) Figure 6. Global GLP-1 Targeted Peptide Weight Loss Drugs Company Revenue Ranking in 2025 (US$ Million) Figure 7. Global Top 5 and 10 Company Market Share by Revenue in 2025 (US$ Million) Figure 8. Company Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 9. Oral Image Figure 10. Injection Image Figure 11. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume by Type (2021 VS 2025 VS 2032) & (K Units) Figure 12. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 13. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume Share by Type (2021-2032) Figure 14. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 15. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 16. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type (2021-2032) Figure 17. Hospital Image Figure 18. Clinic Image Figure 19. Others Image Figure 20. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume by Application (2021 VS 2025 VS 2032) & (K Units) Figure 21. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume Share 2021 VS 2025 VS 2032 Figure 22. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume Share by Application (2021-2032) Figure 23. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 24. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share 2021 VS 2025 VS 2032 Figure 25. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application (2021-2032) Figure 26. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Region: 2021 VS 2025 VS 2032 (K Units) Figure 27. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Market Share by Region: 2021 VS 2025 VS 2032 Figure 28. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Comparison by Region: 2021 VS 2025 VS 2032 (US$ Million) Figure 29. Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Region: 2021 VS 2025 VS 2032 Figure 30. North America GLP-1 Targeted Peptide Weight Loss Drugs Sales Value (2021-2032) & (US$ Million) Figure 31. North America GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 32. Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales Value (2021-2032) & (US$ Million) Figure 33. Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 34. Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales Value (2021-2032) & (US$ Million) Figure 35. Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 36. South America GLP-1 Targeted Peptide Weight Loss Drugs Sales Value (2021-2032) & (US$ Million) Figure 37. South America GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 38. Middle East & Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales Value (2021-2032) & (US$ Million) Figure 39. Middle East & Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Country (%), 2025 VS 2032 Figure 40. USA GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 41. USA GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 42. USA GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 43. Canada GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 44. Canada GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 45. Canada GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 46. Mexico GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 47. Mexico GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 48. Mexico GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 49. Germany GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 50. Germany GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 51. Germany GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 52. France GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 53. France GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 54. France GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 55. U.K. GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 56. U.K. GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 57. U.K. GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 58. Italy GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 59. Italy GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 60. Italy GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 61. Spain GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 62. Spain GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 63. Spain GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 64. Russia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 65. Russia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 66. Russia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 67. Netherlands GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 68. Netherlands GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 69. Netherlands GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 70. Nordic Countries GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 71. Nordic Countries GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 72. Nordic Countries GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 73. China GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 74. China GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 75. China GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 76. Japan GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 77. Japan GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 78. Japan GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 79. South Korea GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 80. South Korea GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 81. South Korea GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 82. India GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 83. India GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 84. India GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 85. Australia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 86. Australia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 87. Australia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 88. Southeast Asia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 89. Southeast Asia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 90. Southeast Asia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 91. Brazil GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 92. Brazil GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 93. Brazil GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 94. Argentina GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 95. Argentina GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 96. Argentina GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 97. Chile GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 98. Chile GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 99. Chile GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 100. Colombia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 101. Colombia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 102. Colombia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 103. Peru GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 104. Peru GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 105. Peru GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 106. Saudi Arabia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 107. Saudi Arabia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 108. Saudi Arabia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 109. Israel GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 110. Israel Arabia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 111. Israel Arabia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 112. UAE GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 113. UAE GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 114. UAE GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 115. Turkey GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 116. Turkey GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 117. Turkey GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 118. Iran GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 119. Iran GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 120. Iran GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 121. Egypt GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032) & (US$ Million) Figure 122. Egypt GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032 & (%) Figure 123. Egypt GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032 & (%) Figure 124. GLP-1 Targeted Peptide Weight Loss Drugs Value Chain Figure 125. Manufacturing Cost Structure Figure 126. GLP-1 Targeted Peptide Weight Loss Drugs Sales Mode & Process Figure 127. Direct Comparison with Distribution Share Figure 128. Distributors Profiles Figure 129. Years Considered Figure 130. Research Process Figure 131. Key Executives Interviewed

Scope & coverage.

Types
  • Oral
  • Injection
Applications
  • Hospital
  • Clinic
  • Others
Companies covered
  • Chugai Pharmaceutical
  • Benemae Pharmaceutical
  • Qilu Pharmaceutical
  • Jiuyuan Gene Engineering
  • Huadong Medicine
  • Zealand Pharma
  • The General Hospital Corp
  • Sanofi-Aventis
  • QuiaPEG Pharmaceuticals Ab
  • Orbis Biosciences
  • Novo Nordisk
  • Nano Precision Medical
  • Nanexa AB
  • Lexaria Bioscience
  • iX Biopharma
  • Intarcia Therapeutics
  • HIKMA PHARMS
  • Eli Lilly
  • Baxter Pharmaceutical
  • Astra Zeneca
  • Amylin Pharmaceuticals

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Global Market Growth Prospects
  3. 1.2.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value (2021-2032)
  4. 1.2.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume (2021-2032)
  5. 1.2.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Average Price (2021-2032)
  6. 1.3 Assumptions and Limitations
  7. 1.4 Study Goals and Objectives
2 GLP-1 Targeted Peptide Weight Loss Drugs Market Dynamics
  1. 2.1 GLP-1 Targeted Peptide Weight Loss Drugs Industry Trends
  2. 2.2 GLP-1 Targeted Peptide Weight Loss Drugs Industry Drivers
  3. 2.3 GLP-1 Targeted Peptide Weight Loss Drugs Industry Opportunities and Challenges
  4. 2.4 GLP-1 Targeted Peptide Weight Loss Drugs Industry Restraints
3 GLP-1 Targeted Peptide Weight Loss Drugs Market by Company
  1. 3.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Company Revenue Ranking in 2025
  2. 3.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Revenue by Company (2021-2026)
  3. 3.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume by Company (2021-2026)
  4. 3.4 Global GLP-1 Targeted Peptide Weight Loss Drugs Average Price by Company (2021-2026)
  5. 3.5 Global GLP-1 Targeted Peptide Weight Loss Drugs Company Ranking (2024-2026)
  6. 3.6 Global GLP-1 Targeted Peptide Weight Loss Drugs Company Manufacturing Base and Headquarters
  7. 3.7 Global GLP-1 Targeted Peptide Weight Loss Drugs Company Product Type and Application
  8. 3.8 Global GLP-1 Targeted Peptide Weight Loss Drugs Company Establishment Date
  9. 3.9 Market Competitive Analysis
  10. 3.9.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Market Concentration Ratio (CR5 and HHI)
  11. 3.9.2 Global Top 5 and 10 Company Market Share by Revenue in 2025
  12. 3.9.3 2025 GLP-1 Targeted Peptide Weight Loss Drugs Tier 1, Tier 2, and Tier 3 Companies
  13. 3.10 Mergers and Acquisitions Expansion
4 GLP-1 Targeted Peptide Weight Loss Drugs Market by Type
  1. 4.1 GLP-1 Targeted Peptide Weight Loss Drugs Type Introduction
  2. 4.1.1 Oral
  3. 4.1.2 Injection
  4. 4.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume by Type
  5. 4.2.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume by Type (2021 VS 2025 VS 2032)
  6. 4.2.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume by Type (2021-2032)
  7. 4.2.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume Share by Type (2021-2032)
  8. 4.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Type
  9. 4.3.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Type (2021 VS 2025 VS 2032)
  10. 4.3.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Type (2021-2032)
  11. 4.3.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type (2021-2032)
5 GLP-1 Targeted Peptide Weight Loss Drugs Market by Application
  1. 5.1 GLP-1 Targeted Peptide Weight Loss Drugs Application Introduction
  2. 5.1.1 Hospital
  3. 5.1.2 Clinic
  4. 5.1.3 Others
  5. 5.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume by Application
  6. 5.2.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume by Application (2021 VS 2025 VS 2032)
  7. 5.2.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume by Application (2021-2032)
  8. 5.2.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Volume Share by Application (2021-2032)
  9. 5.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Application
  10. 5.3.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Application (2021 VS 2025 VS 2032)
  11. 5.3.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Application (2021-2032)
  12. 5.3.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application (2021-2032)
6 GLP-1 Targeted Peptide Weight Loss Drugs Regional Sales and Value Analysis
  1. 6.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Region: 2021 VS 2025 VS 2032
  2. 6.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Region (2021-2032)
  3. 6.2.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Region: 2021-2026
  4. 6.2.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Region (2027-2032)
  5. 6.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Region: 2021 VS 2025 VS 2032
  6. 6.4 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Region (2021-2032)
  7. 6.4.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Region: 2021-2026
  8. 6.4.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Region (2027-2032)
  9. 6.5 Global GLP-1 Targeted Peptide Weight Loss Drugs Market Price Analysis by Region (2021-2026)
  10. 6.6 North America
  11. 6.6.1 North America GLP-1 Targeted Peptide Weight Loss Drugs Sales Value (2021-2032)
  12. 6.6.2 North America GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Country, 2025 VS 2032
  13. 6.7 Europe
  14. 6.7.1 Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales Value (2021-2032)
  15. 6.7.2 Europe GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Country, 2025 VS 2032
  16. 6.8 Asia-Pacific
  17. 6.8.1 Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales Value (2021-2032)
  18. 6.8.2 Asia-Pacific GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Country, 2025 VS 2032
  19. 6.9 South America
  20. 6.9.1 South America GLP-1 Targeted Peptide Weight Loss Drugs Sales Value (2021-2032)
  21. 6.9.2 South America GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Country, 2025 VS 2032
  22. 6.10 Middle East & Africa
  23. 6.10.1 Middle East & Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales Value (2021-2032)
  24. 6.10.2 Middle East & Africa GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Country, 2025 VS 2032
7 GLP-1 Targeted Peptide Weight Loss Drugs Country-level Sales and Value Analysis
  1. 7.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country: 2021 VS 2025 VS 2032
  2. 7.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Country: 2021 VS 2025 VS 2032
  3. 7.3 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2021-2032)
  4. 7.3.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2021-2026)
  5. 7.3.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales by Country (2027-2032)
  6. 7.4 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Country (2021-2032)
  7. 7.4.1 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Country (2021-2026)
  8. 7.4.2 Global GLP-1 Targeted Peptide Weight Loss Drugs Sales Value by Country (2027-2032)
  9. 7.5 USA
  10. 7.5.1 USA GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032)
  11. 7.5.2 USA GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032
  12. 7.5.3 USA GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032
  13. 7.6 Canada
  14. 7.6.1 Canada GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032)
  15. 7.6.2 Canada GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032
  16. 7.6.3 Canada GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032
  17. 7.7 Mexico
  18. 7.6.1 Mexico GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032)
  19. 7.6.2 Mexico GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032
  20. 7.6.3 Mexico GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032
  21. 7.8 Germany
  22. 7.8.1 Germany GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032)
  23. 7.8.2 Germany GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032
  24. 7.8.3 Germany GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032
  25. 7.9 France
  26. 7.9.1 France GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032)
  27. 7.9.2 France GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032
  28. 7.9.3 France GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032
  29. 7.10 U.K.
  30. 7.10.1 U.K. GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032)
  31. 7.10.2 U.K. GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032
  32. 7.10.3 U.K. GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032
  33. 7.11 Italy
  34. 7.11.1 Italy GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032)
  35. 7.11.2 Italy GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032
  36. 7.11.3 Italy GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032
  37. 7.12 Spain
  38. 7.12.1 Spain GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032)
  39. 7.12.2 Spain GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032
  40. 7.12.3 Spain GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032
  41. 7.13 Russia
  42. 7.13.1 Russia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032)
  43. 7.13.2 Russia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032
  44. 7.13.3 Russia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032
  45. 7.14 Netherlands
  46. 7.14.1 Netherlands GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032)
  47. 7.14.2 Netherlands GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032
  48. 7.14.3 Netherlands GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032
  49. 7.15 Nordic Countries
  50. 7.15.1 Nordic Countries GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032)
  51. 7.15.2 Nordic Countries GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032
  52. 7.15.3 Nordic Countries GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032
  53. 7.16 China
  54. 7.16.1 China GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032)
  55. 7.16.2 China GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032
  56. 7.16.3 China GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032
  57. 7.17 Japan
  58. 7.17.1 Japan GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032)
  59. 7.17.2 Japan GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032
  60. 7.17.3 Japan GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032
  61. 7.18 South Korea
  62. 7.18.1 South Korea GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032)
  63. 7.18.2 South Korea GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032
  64. 7.18.3 South Korea GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032
  65. 7.19 India
  66. 7.19.1 India GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032)
  67. 7.19.2 India GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032
  68. 7.19.3 India GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032
  69. 7.20 Australia
  70. 7.20.1 Australia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032)
  71. 7.20.2 Australia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032
  72. 7.20.3 Australia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032
  73. 7.21 Southeast Asia
  74. 7.21.1 Southeast Asia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032)
  75. 7.21.2 Southeast Asia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032
  76. 7.21.3 Southeast Asia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032
  77. 7.22 Brazil
  78. 7.22.1 Brazil GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032)
  79. 7.22.2 Brazil GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032
  80. 7.22.3 Brazil GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032
  81. 7.23 Argentina
  82. 7.23.1 Argentina GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032)
  83. 7.23.2 Argentina GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032
  84. 7.23.3 Argentina GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032
  85. 7.24 Chile
  86. 7.24.1 Chile GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032)
  87. 7.24.2 Chile GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032
  88. 7.24.3 Chile GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032
  89. 7.25 Colombia
  90. 7.25.1 Colombia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032)
  91. 7.25.2 Colombia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032
  92. 7.25.3 Colombia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032
  93. 7.26 Peru
  94. 7.26.1 Peru GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032)
  95. 7.26.2 Peru GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032
  96. 7.26.3 Peru GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032
  97. 7.27 Saudi Arabia
  98. 7.27.1 Saudi Arabia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032)
  99. 7.27.2 Saudi Arabia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032
  100. 7.27.3 Saudi Arabia GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032
  101. 7.28 Israel
  102. 7.28.1 Israel GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032)
  103. 7.28.2 Israel GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032
  104. 7.28.3 Israel GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032
  105. 7.29 UAE
  106. 7.29.1 UAE GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032)
  107. 7.29.2 UAE GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032
  108. 7.29.3 UAE GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032
  109. 7.30 Turkey
  110. 7.30.1 Turkey GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032)
  111. 7.30.2 Turkey GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032
  112. 7.30.3 Turkey GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032
  113. 7.31 Iran
  114. 7.31.1 Iran GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032)
  115. 7.31.2 Iran GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032
  116. 7.31.3 Iran GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032
  117. 7.32 Egypt
  118. 7.32.1 Egypt GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Growth Rate (2021-2032)
  119. 7.32.2 Egypt GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Type, 2025 VS 2032
  120. 7.32.3 Egypt GLP-1 Targeted Peptide Weight Loss Drugs Sales Value Share by Application, 2025 VS 2032
8 Company Profiles
  1. 8.1 Chugai Pharmaceutical
  2. 8.1.1 Chugai Pharmaceutical Company Information
  3. 8.1.2 Chugai Pharmaceutical Business Overview
  4. 8.1.3 Chugai Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2021-2026)
  5. 8.1.4 Chugai Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  6. 8.1.5 Chugai Pharmaceutical Recent Developments
  7. 8.2 Benemae Pharmaceutical
  8. 8.2.1 Benemae Pharmaceutical Company Information
  9. 8.2.2 Benemae Pharmaceutical Business Overview
  10. 8.2.3 Benemae Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2021-2026)
  11. 8.2.4 Benemae Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  12. 8.2.5 Benemae Pharmaceutical Recent Developments
  13. 8.3 Qilu Pharmaceutical
  14. 8.3.1 Qilu Pharmaceutical Company Information
  15. 8.3.2 Qilu Pharmaceutical Business Overview
  16. 8.3.3 Qilu Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2021-2026)
  17. 8.3.4 Qilu Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  18. 8.3.5 Qilu Pharmaceutical Recent Developments
  19. 8.4 Jiuyuan Gene Engineering
  20. 8.4.1 Jiuyuan Gene Engineering Company Information
  21. 8.4.2 Jiuyuan Gene Engineering Business Overview
  22. 8.4.3 Jiuyuan Gene Engineering GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2021-2026)
  23. 8.4.4 Jiuyuan Gene Engineering GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  24. 8.4.5 Jiuyuan Gene Engineering Recent Developments
  25. 8.5 Huadong Medicine
  26. 8.5.1 Huadong Medicine Company Information
  27. 8.5.2 Huadong Medicine Business Overview
  28. 8.5.3 Huadong Medicine GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2021-2026)
  29. 8.5.4 Huadong Medicine GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  30. 8.5.5 Huadong Medicine Recent Developments
  31. 8.6 Zealand Pharma
  32. 8.6.1 Zealand Pharma Company Information
  33. 8.6.2 Zealand Pharma Business Overview
  34. 8.6.3 Zealand Pharma GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2021-2026)
  35. 8.6.4 Zealand Pharma GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  36. 8.6.5 Zealand Pharma Recent Developments
  37. 8.7 The General Hospital Corp
  38. 8.7.1 The General Hospital Corp Company Information
  39. 8.7.2 The General Hospital Corp Business Overview
  40. 8.7.3 The General Hospital Corp GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2021-2026)
  41. 8.7.4 The General Hospital Corp GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  42. 8.7.5 The General Hospital Corp Recent Developments
  43. 8.8 Sanofi-Aventis
  44. 8.8.1 Sanofi-Aventis Company Information
  45. 8.8.2 Sanofi-Aventis Business Overview
  46. 8.8.3 Sanofi-Aventis GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2021-2026)
  47. 8.8.4 Sanofi-Aventis GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  48. 8.8.5 Sanofi-Aventis Recent Developments
  49. 8.9 QuiaPEG Pharmaceuticals Ab
  50. 8.9.1 QuiaPEG Pharmaceuticals Ab Company Information
  51. 8.9.2 QuiaPEG Pharmaceuticals Ab Business Overview
  52. 8.9.3 QuiaPEG Pharmaceuticals Ab GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2021-2026)
  53. 8.9.4 QuiaPEG Pharmaceuticals Ab GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  54. 8.9.5 QuiaPEG Pharmaceuticals Ab Recent Developments
  55. 8.10 Orbis Biosciences
  56. 8.10.1 Orbis Biosciences Company Information
  57. 8.10.2 Orbis Biosciences Business Overview
  58. 8.10.3 Orbis Biosciences GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2021-2026)
  59. 8.10.4 Orbis Biosciences GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  60. 8.10.5 Orbis Biosciences Recent Developments
  61. 8.11 Novo Nordisk
  62. 8.11.1 Novo Nordisk Company Information
  63. 8.11.2 Novo Nordisk Business Overview
  64. 8.11.3 Novo Nordisk GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2021-2026)
  65. 8.11.4 Novo Nordisk GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  66. 8.11.5 Novo Nordisk Recent Developments
  67. 8.12 Nano Precision Medical
  68. 8.12.1 Nano Precision Medical Company Information
  69. 8.12.2 Nano Precision Medical Business Overview
  70. 8.12.3 Nano Precision Medical GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2021-2026)
  71. 8.12.4 Nano Precision Medical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  72. 8.12.5 Nano Precision Medical Recent Developments
  73. 8.13 Nanexa AB
  74. 8.13.1 Nanexa AB Company Information
  75. 8.13.2 Nanexa AB Business Overview
  76. 8.13.3 Nanexa AB GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2021-2026)
  77. 8.13.4 Nanexa AB GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  78. 8.13.5 Nanexa AB Recent Developments
  79. 8.14 Lexaria Bioscience
  80. 8.14.1 Lexaria Bioscience Company Information
  81. 8.14.2 Lexaria Bioscience Business Overview
  82. 8.14.3 Lexaria Bioscience GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2021-2026)
  83. 8.14.4 Lexaria Bioscience GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  84. 8.14.5 Lexaria Bioscience Recent Developments
  85. 8.15 iX Biopharma
  86. 8.15.1 iX Biopharma Company Information
  87. 8.15.2 iX Biopharma Business Overview
  88. 8.15.3 iX Biopharma GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2021-2026)
  89. 8.15.4 iX Biopharma GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  90. 8.15.5 iX Biopharma Recent Developments
  91. 8.16 Intarcia Therapeutics
  92. 8.16.1 Intarcia Therapeutics Company Information
  93. 8.16.2 Intarcia Therapeutics Business Overview
  94. 8.16.3 Intarcia Therapeutics GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2021-2026)
  95. 8.16.4 Intarcia Therapeutics GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  96. 8.16.5 Intarcia Therapeutics Recent Developments
  97. 8.17 HIKMA PHARMS
  98. 8.17.1 HIKMA PHARMS Company Information
  99. 8.17.2 HIKMA PHARMS Business Overview
  100. 8.17.3 HIKMA PHARMS GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2021-2026)
  101. 8.17.4 HIKMA PHARMS GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  102. 8.17.5 HIKMA PHARMS Recent Developments
  103. 8.18 Eli Lilly
  104. 8.18.1 Eli Lilly Company Information
  105. 8.18.2 Eli Lilly Business Overview
  106. 8.18.3 Eli Lilly GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2021-2026)
  107. 8.18.4 Eli Lilly GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  108. 8.18.5 Eli Lilly Recent Developments
  109. 8.19 Baxter Pharmaceutical
  110. 8.19.1 Baxter Pharmaceutical Company Information
  111. 8.19.2 Baxter Pharmaceutical Business Overview
  112. 8.19.3 Baxter Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2021-2026)
  113. 8.19.4 Baxter Pharmaceutical GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  114. 8.19.5 Baxter Pharmaceutical Recent Developments
  115. 8.20 Astra Zeneca
  116. 8.20.1 Astra Zeneca Company Information
  117. 8.20.2 Astra Zeneca Business Overview
  118. 8.20.3 Astra Zeneca GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2021-2026)
  119. 8.20.4 Astra Zeneca GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  120. 8.20.5 Astra Zeneca Recent Developments
  121. 8.21 Amylin Pharmaceuticals
  122. 8.21.1 Amylin Pharmaceuticals Company Information
  123. 8.21.2 Amylin Pharmaceuticals Business Overview
  124. 8.21.3 Amylin Pharmaceuticals GLP-1 Targeted Peptide Weight Loss Drugs Sales, Value and Gross Margin (2021-2026)
  125. 8.21.4 Amylin Pharmaceuticals GLP-1 Targeted Peptide Weight Loss Drugs Product Portfolio
  126. 8.21.5 Amylin Pharmaceuticals Recent Developments
9 Value Chain and Sales Channels Analysis
  1. 9.1 GLP-1 Targeted Peptide Weight Loss Drugs Value Chain Analysis
  2. 9.1.1 GLP-1 Targeted Peptide Weight Loss Drugs Key Raw Materials
  3. 9.1.2 Raw Materials Key Suppliers
  4. 9.1.3 Manufacturing Cost Structure
  5. 9.1.4 GLP-1 Targeted Peptide Weight Loss Drugs Sales Mode & Process
  6. 9.2 GLP-1 Targeted Peptide Weight Loss Drugs Sales Channels Analysis
  7. 9.2.1 Direct Comparison with Distribution Share
  8. 9.2.2 GLP-1 Targeted Peptide Weight Loss Drugs Distributors
  9. 9.2.3 GLP-1 Targeted Peptide Weight Loss Drugs Customers
10 Concluding Insights
    11 Appendix
    1. 11.1 Reasons for Doing This Study
    2. 11.2 Research Methodology
    3. 11.3 Research Process
    4. 11.4 Authors List of This Report
    5. 11.5 Data Source
    6. 11.5.1 Secondary Sources
    7. 11.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,250USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst